Kalfin R, Maulik N, Engelman R M, Cordis G A, Milenov K, Kasakov L, Das D K
Department of Surgery, University of Connecticut School of Medicine, Farmington.
J Pharmacol Exp Ther. 1994 Feb;268(2):952-8.
Vasoactive intestinal peptide (VIP) has been shown to exert vasodilatory action and positive ionotropic effect on the heart and to possess free radical-scavenging ability. Because these properties are likely to make this peptide a suitable agent for myocardial preservation, we examined the role of VIP in myocardial ischemia and reperfusion. Isolated rat heart perfused by the Langendorff technique was subjected to 30 min of normothermic ischemia followed by 60 min of reperfusion. A significant amount of VIP was found to be released from the ischemic reperfused heart. The amount of VIP released from the heart increased progressively with the duration of reperfusion and paralleled the release of creative kinase from the heart. In another set of experiments, hearts were divided into two groups. The experimental group received three different doses of VIP (0.1 microM, 0.3 microM and 1 microM) before ischemia. After perfusing the isolated heart with VIP for 15 min, ischemia was induced for 30 min by terminating the coronary flow, which was followed by 60 min of reperfusion. The results of our study indicated a significant improvement of myocardial functions by VIP (0.3 and 1 microM), as evidenced by enhanced left ventricular functions and coronary flow, and reduction of tissue injury, as judged by the decrease in creatine kinase release (0.3 microM only). Intracellular Ca++ ([Ca++]i) transients increased during ischemia and further increased during reperfusion. The increase in [Ca++]i transients was significantly reduced in the VIP-treated hearts. A significant amount of hydroxyl radical was detected in the ischemic reperfused heart, but the quantity of the hydroxyl radical was much lower in the VIP-treated group.(ABSTRACT TRUNCATED AT 250 WORDS)
血管活性肠肽(VIP)已被证明具有血管舒张作用,对心脏有正性变力效应,并具有清除自由基的能力。由于这些特性可能使该肽成为一种适合心肌保护的药物,我们研究了VIP在心肌缺血和再灌注中的作用。采用Langendorff技术灌注的离体大鼠心脏经历30分钟的常温缺血,随后再灌注60分钟。发现有大量VIP从缺血再灌注心脏中释放出来。心脏释放的VIP量随着再灌注时间的延长而逐渐增加,并与心脏中肌酸激酶的释放平行。在另一组实验中,将心脏分为两组。实验组在缺血前接受三种不同剂量的VIP(0.1微摩尔/升、0.3微摩尔/升和1微摩尔/升)。用VIP灌注离体心脏15分钟后,通过终止冠状动脉血流诱导缺血30分钟,随后再灌注60分钟。我们的研究结果表明,VIP(0.3和1微摩尔/升)能显著改善心肌功能,表现为左心室功能和冠状动脉血流增强,组织损伤减轻(仅0.3微摩尔/升时肌酸激酶释放减少)。缺血期间细胞内Ca++([Ca++]i)瞬变增加,再灌注期间进一步增加。VIP处理的心脏中[Ca++]i瞬变的增加显著减少。在缺血再灌注心脏中检测到大量羟自由基,但VIP处理组中的羟自由基数量要低得多。(摘要截断于250字)